'The CPSC is aware of 10 infant deaths in the Rock 'N Play that have occurred since 2015, after the infants rolled from their back to their stomach or side, while unrestrained'
Mattel Inc. MAT, +0.22% subsidiary Fisher-Price Inc. and the Consumer Product Safety Commission warned consumers to stop using the Fisher-Price's Rock 'N Play when infants can roll over, after multiple reports of death. Industry experts have said infants typically begin rolling over at three months.
Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Fisher-Price says 10 infants have died using Rock 'n Play sleeperA safety group asks customers to stop using Fisher-Price Rock 'n Play sleeper after 10 infants reportedly died in it since 2015
Read more »
Fisher-Price issues warning about Rock 'N Play sleeper after 10 infants dieParents who put their infants to sleep in the Fisher-Price Rock 'N Play inclined sleeper are being warned about the product after 10 children have died in it since 2015.
Read more »
Fisher-Price Is Warning Parents After 10 Babies Died In The Rock 'N Play SleeperInfants who can roll over by themselves should not be put in a Rock 'n Play sleeper.
Read more »
10 infants die from Fisher-Price sleeper, company issues warningParents who put their infants to sleep in the Fisher-Price Rock 'N Play inclined sleeper are being warned about the product after 10 children have died in it since 2015.
Read more »
New insulin price won't top $25 a month out-of-pocket, Cigna saysHealth insurer Cigna is launching a program that will cap out-of-pocket expenses at $25 for a 30-day supply of insulin
Read more »
Less than 8 percent of students chose a college based on priceStudents prioritize location and 'fit' of their college over price. Experts say affordability should get more attention.
Read more »
Lyft plunges below IPO price, sending cautionary message to other unicorns“This is a technical black eye,” one analyst says.“Investors will not forget.'
Read more »
Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. groupBiogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and...
Read more »